Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

Rhea-AI Summary

Apyx Medical (NASDAQ:APYX) will release fourth-quarter fiscal 2025 financial results before markets open on March 10, 2026. Management will host a conference call and webcast at 8:00 a.m. ET the same day to discuss results and take questions.

Phone dial‑in access, an international number, and an archived webcast will be available via the company’s investor relations site.

News Market Reaction – APYX

-3.39%

-3.39% Session close to close

In the Feb 25 session, APYX declined 3.39%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules the release of Apyx Medical’s Q4 and full‑year 2025 results and an accom...

Analysis

This announcement schedules the release of Apyx Medical’s Q4 and full‑year 2025 results and an accompanying conference call. It follows January’s preliminary revenue update, which showed notable growth in Surgical Aesthetics. Investors may focus on audited revenue, profitability trends, and cash usage, as well as any color on AYON’s commercial rollout and international expansion. Monitoring follow‑up disclosures, capital allocation decisions, and product adoption metrics could be important as the formal results are issued.

Key Figures

Earnings release date: March 10 Earnings call time: 8:00 a.m. Eastern Time Access code: 81823 +1 more

4 metrics

Earnings release date March 10 Q4 fiscal year 2025 results to be released before market open

Earnings call time 8:00 a.m. Eastern Time Start time of Q4 FY 2025 conference call

Access code 81823 Telephone access code for the Apyx Medical Corporation call

Clinical documents More than 90 Clinical documents supporting effectiveness of Renuvion and J-Plasma

Historical Context

5 past events · Latest: Feb 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 18	Conference participation	Positive	+2.1%	Management participation in Citizens Life Sciences Conference and investor meetings.
Jan 29	Conference participation	Positive	+1.0%	Announcement of participation in BTIG MedTech and related investor outreach.
Jan 12	Prelim revenue update	Positive	+14.9%	Preliminary Q4 and full-year 2025 revenue with strong Surgical Aesthetics growth.
Dec 03	Intl product launch	Positive	-1.7%	MFDS approval and launch of Apyx One console in South Korea cosmetic surgery market.
Nov 18	Equity offering	Negative	-5.5%	Pricing of $10M common stock offering at $3.62 under existing registration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent APYX news has mostly seen price moves align with the underlying news tone, with only one divergence on a positive international launch announcement.

Recent Company History

Over the last few months, APYX has highlighted conference participation, strong preliminary Q4 and FY 2025 revenue, international expansion, and an equity offering. The preliminary revenue update on Jan 12, 2026 drew the strongest reaction at +14.9%, while the November $10M offering saw a -5.46% move. Today’s earnings date notice follows that trajectory, setting up the formal release of audited 2025 results already previewed in January.

Key Terms

fiscal year, fda-cleared, oem agreements

3 terms

fiscal year financial

"financial results for the fourth quarter of fiscal year 2025 will be released"

A fiscal year is a 12-month period that companies and governments use for financial planning and reporting, which might not match the calendar year (January to December). It’s like a school year that starts in one month and ends in another—helping organizations track their income, expenses, and budgets over a specific period.

fda-cleared regulatory

"The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

oem agreements financial

"leverages its deep expertise and decades of experience in unique waveforms through OEM agreements"

OEM agreements are contracts where one company makes products or components that another company sells under its own brand, like a bakery baking cakes that a café sells with the café’s name. For investors, these deals matter because they influence cost structure, product quality, supply reliability and how much control a brand has over manufacturing; strong OEM partnerships can speed growth but can also create dependence on outside suppliers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System^™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th.

Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10^th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81823. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System^™ in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com  

FAQ

When will Apyx Medical (APYX) release Q4 fiscal 2025 results and host the earnings call?

Apyx Medical will release Q4 fiscal 2025 results before markets open on March 10, 2026. According to Apyx Medical, management will host a conference call and webcast at 8:00 a.m. ET that day to discuss the quarter and take questions.

How can investors access the Apyx Medical (APYX) March 10, 2026 earnings call and webcast?

Investors can listen by phone using the provided domestic and international numbers or via a live webcast. According to Apyx Medical, the call will be archived in the company’s Investor Relations section for later replay.

What topics will Apyx Medical (APYX) management cover on the March 10, 2026 conference call?

Management will discuss fourth-quarter fiscal 2025 financial results and answer analyst and investor questions. According to Apyx Medical, the session includes a formal results presentation followed by a question‑and‑answer period with management.

What products and technologies does Apyx Medical (APYX) highlight that investors should note?

Apyx Medical markets its Helium Plasma Platform products, including Renuvion, J‑Plasma, and the FDA‑cleared AYON Body Contouring System. According to Apyx Medical, these products are supported by more than 90 clinical documents.

Will the Apyx Medical (APYX) earnings call on March 10, 2026 be recorded for later viewing?

Yes, the earnings call will be archived for later viewing on the company website. According to Apyx Medical, the live webcast will be accessible and archived in the Investor Relations area for future reference.